M. Kanarek, Mesothelioma from Chrysotile Asbestos: Update, Annals of Epidemiology, vol.21, issue.9, pp.688-97, 2011.
DOI : 10.1016/j.annepidem.2011.05.010

B. Robinson and R. Lake, Advances in Malignant Mesothelioma, New England Journal of Medicine, vol.353, issue.15, pp.1591-603, 2005.
DOI : 10.1056/NEJMra050152

N. Vogelzang, Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, Journal of Clinical Oncology, vol.21, issue.14, pp.2636-2680, 2003.
DOI : 10.1200/JCO.2003.11.136

M. De-perrot, Risk Factors for Major Complications After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma, The Annals of Thoracic Surgery, vol.85, issue.4, pp.1206-1216, 2008.
DOI : 10.1016/j.athoracsur.2007.11.065

M. De-perrot, Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma, The Journal of Thoracic and Cardiovascular Surgery, vol.133, issue.1, pp.111-117, 2007.
DOI : 10.1016/j.jtcvs.2006.06.044

M. De-perrot, Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma, Journal of Clinical Oncology, vol.27, issue.9, pp.1413-1421, 2009.
DOI : 10.1200/JCO.2008.17.5604

K. Ribi, Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: Feasibility and responsiveness to clinical changes, Lung Cancer, vol.61, issue.3, pp.398-404, 2008.
DOI : 10.1016/j.lungcan.2008.01.013

B. Cho, A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The ???SMART??? Approach for Resectable Malignant Pleural Mesothelioma, Journal of Thoracic Oncology, vol.9, issue.3, pp.397-402, 2014.
DOI : 10.1097/JTO.0000000000000078

M. Anraku, Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma, The Journal of Immunology, vol.185, issue.2, pp.956-66, 2010.
DOI : 10.4049/jimmunol.0900437

L. Wu, Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T-Cell Depletion in a Murine Mesothelioma Model, Journal of Thoracic Oncology, vol.6, issue.9, pp.1578-86, 2011.
DOI : 10.1097/JTO.0b013e3182208ee0

L. Wu, CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma, Molecular Cancer Therapeutics, vol.11, issue.8, pp.1809-1828, 2012.
DOI : 10.1158/1535-7163.MCT-11-1014

T. Tagawa, Antitumor Impact of Interferon-?? Producing CD1d-restricted NKT Cells in Murine Malignant Mesothelioma, Journal of Immunotherapy, vol.36, issue.8, pp.391-400, 2013.
DOI : 10.1097/CJI.0b013e3182a801f2

L. Wu, Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma, Cancer Immunology, Immunotherapy, vol.2, issue.12, pp.1285-96, 2014.
DOI : 10.4161/onci.22615

L. Wu, Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model, Oncotarget, vol.6, issue.14, pp.12468-80, 2015.
DOI : 10.18632/oncotarget.3487

W. Licun and I. Tannock, Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy, Clin Cancer Res, vol.9, issue.12, pp.4614-4622, 2003.

L. Wu and I. Tannock, Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil, Cancer Res, vol.63, issue.9, pp.2134-2142, 2003.

A. Fung, L. Wu, and I. Tannock, Concurrent and Sequential Administration of Chemotherapy and the Mammalian Target of Rapamycin Inhibitor Temsirolimus in Human Cancer Cells and Xenografts, Clinical Cancer Research, vol.15, issue.17, pp.5389-95, 2009.
DOI : 10.1158/1078-0432.CCR-08-3007

L. Wu and I. Tannock, Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy, Clinical Cancer Research, vol.11, issue.22, pp.8195-200, 2005.
DOI : 10.1158/1078-0432.CCR-05-1258

L. Wu, D. Birle, and I. Tannock, Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts, Cancer Research, vol.65, issue.7, pp.2825-2856, 2005.
DOI : 10.1158/0008-5472.CAN-04-3137

A. Hovden and S. Appel, The First Dendritic Cell-Based Therapeutic Cancer Vaccine is Approved by the FDA, Scandinavian Journal of Immunology, vol.24, issue.6, p.554, 2010.
DOI : 10.1111/j.1365-3083.2010.02464.x

URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-3083.2010.02464.x/pdf

S. Prashad, GPI-80 Defines Self-Renewal Ability in Hematopoietic Stem Cells during Human Development, Cell Stem Cell, vol.16, issue.1, pp.80-87, 2015.
DOI : 10.1016/j.stem.2014.10.020

URL : https://doi.org/10.1016/j.stem.2014.10.020

E. Pasdar, Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents, PLoS One, vol.10, issue.5, p.119549, 2015.
DOI : 10.1371/journal.pone.0119549

URL : https://doi.org/10.1371/journal.pone.0119549

E. Dotse and Y. Bian, Isolation of colorectal cancer stem-like cells, Cytotechnology, vol.457, issue.4, pp.609-619, 2014.
DOI : 10.1038/nature07589

A. Hotta, EOS lentiviral vector selection system for human induced pluripotent stem cells, Nature Protocols, vol.73, issue.12, pp.1828-1872, 2009.
DOI : 10.1016/0022-1759(86)90278-4

W. Blum, Stem Cell Factor-Based Identification and Functional Properties of In??Vitro-Selected Subpopulations of Malignant Mesothelioma Cells, Stem Cell Reports, vol.8, issue.4, pp.1005-1022, 2017.
DOI : 10.1016/j.stemcr.2017.02.005

A. Shahryari, Two Novel Splice Variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are Coupregulated with SOX2 and OCT4 in Esophageal Squamous Cell Carcinoma, STEM CELLS, vol.11, issue.1, pp.126-160, 2014.
DOI : 10.1186/1471-2202-11-14

URL : http://onlinelibrary.wiley.com/doi/10.1002/stem.1542/pdf

W. Blum, Establishment of immortalized murine mesothelial cells and a novel mesothelioma cell line, In Vitro Cellular & Developmental Biology - Animal, vol.20, issue.7, pp.714-735, 2015.
DOI : 10.1007/s11248-010-9403-8

URL : https://link.springer.com/content/pdf/10.1007%2Fs11626-015-9885-z.pdf

C. Thieke, Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy, Radiation Oncology, vol.91, issue.11, p.267, 2015.
DOI : 10.1016/j.ijrobp.2014.08.343

URL : https://ro-journal.biomedcentral.com/track/pdf/10.1186/s13014-015-0575-5?site=ro-journal.biomedcentral.com

M. De-perrot, Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma, The Journal of Thoracic and Cardiovascular Surgery, vol.151, issue.2, pp.468-73, 2016.
DOI : 10.1016/j.jtcvs.2015.09.129

L. Wu, Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma, Clinical Cancer Research, vol.23, issue.4, pp.1060-1067, 2017.
DOI : 10.1158/1078-0432.CCR-16-0844

A. Guazzelli, Tremelimumab for the treatment of malignant mesothelioma, Expert Opinion on Biological Therapy, vol.11, issue.2, pp.1819-1848, 2015.
DOI : 10.1371/journal.pone.0053745

, A Potential Immune Therapy for Mesothelioma):OF14. https://doi, Cancer Discov, vol.5, issue.7, 2015.

L. De-la-maza, M. Wu, L. Wu, H. Yun, Y. Zhao et al., Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model, Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model, pp.5502-5513, 2017.
DOI : 10.1158/1078-0432.CCR-17-0438

I. Tannock, Resistance through repopulation, Nature, vol.36, issue.7533, pp.152-155, 2015.
DOI : 10.1016/j.clinthera.2014.06.015

J. Saggar and I. Tannock, Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation--An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302, Clinical Cancer Research, vol.21, issue.9, pp.2107-2121, 2015.
DOI : 10.1158/1078-0432.CCR-14-2298

Q. Zhao, Prognostic value of the expression of cancer stem cell-related markers CD133 and CD44 in hepatocellular carcinoma: From patients to patient-derived tumor xenograft models, Oncotarget, vol.7, issue.30, pp.47431-47443, 2016.
DOI : 10.18632/oncotarget.10164

F. Zhou, Tracing haematopoietic stem cell formation at single-cell resolution, Nature, vol.13, issue.7604, pp.487-92, 2016.
DOI : 10.1101/gr.1239303

H. Shigeishi, Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3?? influenced by CD44 and RHAMM, STEM CELLS, vol.9, issue.10, pp.2073-83, 2013.
DOI : 10.1186/1476-4598-9-162

J. Wang, A protein interaction network for pluripotency of embryonic stem cells, Nature, vol.579, issue.7117, pp.364-372, 2006.
DOI : 10.1016/j.febslet.2005.02.020

L. Boyer, Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells, Cell, vol.122, issue.6, pp.947-56, 2005.
DOI : 10.1016/j.cell.2005.08.020

URL : https://doi.org/10.1016/j.cell.2005.08.020

K. Woltjen, piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells, Nature, vol.27, issue.7239, pp.766-70, 2009.
DOI : 10.1038/nature07863

URL : http://europepmc.org/articles/pmc3758996?pdf=render

D. Ovchinnikov, Transgenic human ES and iPS reporter cell lines for identification and selection of pluripotent stem cells in vitro, Stem Cell Research, vol.13, issue.2, pp.251-61, 2014.
DOI : 10.1016/j.scr.2014.05.006

V. Shinde, Simulated Microgravity Modulates Differentiation Processes of Embryonic Stem Cells, Cellular Physiology and Biochemistry, vol.38, issue.4, pp.1483-99, 2016.
DOI : 10.1159/000443090

URL : https://doi.org/10.1159/000443090

W. Chen, Malignant Transformation Initiated by Mll-AF9: Gene Dosage and Critical Target Cells, Cancer Cell, vol.13, issue.5, pp.432-472, 2008.
DOI : 10.1016/j.ccr.2008.03.005

URL : https://doi.org/10.1016/j.ccr.2008.03.005

W. Kratky, Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination, Proceedings of the National Academy of Sciences, vol.118, issue.6, pp.17414-17423, 2011.
DOI : 10.1172/JCI34584

URL : http://www.pnas.org/content/108/42/17414.full.pdf

B. Carreno, IL-12p70???producing patient DC vaccine elicits Tc1-polarized immunity, Journal of Clinical Investigation, vol.123, issue.8, pp.3383-94, 2013.
DOI : 10.1172/JCI68395DS1

URL : http://www.jci.org/articles/view/68395/files/pdf

E. Voest, Inhibition of Angiogenesis In Vivo by Interleukin 12, JNCI Journal of the National Cancer Institute, vol.87, issue.8, pp.581-587, 1995.
DOI : 10.1093/jnci/87.8.581

S. Nguyen, Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations, Onco Targets Ther, vol.8, pp.323-357, 2015.

A. Kotini, Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia, Cell Stem Cell, vol.20, issue.3, pp.315-343, 2017.
DOI : 10.1016/j.stem.2017.01.009

R. Lynn, High-affinity FR??-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity, Leukemia, vol.93, issue.6, pp.1355-64, 2016.
DOI : 10.1158/2326-6066.CIR-13-0006

URL : http://europepmc.org/articles/pmc4889499?pdf=render